Drugs /

pertuzumab

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
pertuzumab
Trade Name(s):
Perjeta and Omnitarg
NCI Definition [1]:
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for pertuzumab

Pertuzumab has been investigated in 90 clinical trials, of which 66 are open and 24 are closed. Of the trials investigating pertuzumab, 2 are early phase 1 (1 open), 10 are phase 1 (7 open), 13 are phase 1/phase 2 (9 open), 47 are phase 2 (34 open), 16 are phase 3 (13 open), and 2 are no phase specified (2 open).

ERBB2 Amplification, HER2 Positive, and HER2 Overexpression are the most frequent biomarker inclusion criteria for pertuzumab clinical trials.

Breast carcinoma, invasive breast carcinoma, and breast adenocarcinoma are the most common diseases being investigated in pertuzumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pertuzumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pertuzumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pertuzumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
moab 2c4, Perjeta, Omnitarg, 2c4 antibody, moab 2c4, pertuzumab, 2c4, monoclonal antibody 2c4, pertuzumab, monoclonal antibody 2c4, rhumab2c4, rhumab 2c4, ro4368451, immunoglobulin g1, anti-(human v (receptor)) (human-mouse monoclonal 2c4 heavy chain), disulfide with human-mouse monoclonal 2c4 kappa-chain, dimer, pertuzumab (product), 2c4 antibody, pertuzumab (substance), rhumab-2c4
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
ERBB2
NCIT ID [1]:
C38692
SNOMED ID [1]:
R-FC1A2

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.